INNOVENT ANNOUNCES FIRST PATIENT DOSED IN PIVOTAL REGISTRATIONAL STUDY OF IBI363/TAK-928 (PD-1/IL-2Α-BIASED BISPECIFIC FUSION PROTEIN) IN COMBINATION WITH BEVACIZUMAB IN LATE-LINE ADVANCED COLORECTAL CANCER IN CHINA

Reuters · 2d ago

Please log in to view news